Patent 11970540 was granted and assigned to TeneoBio on April, 2024 by the United States Patent and Trademark Office.
Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.